Non-selective Metabotropic Glutamate
Agonists |
|
|---|---|
| Cat No | Product Name / Activity |
| 0216 | L-Cysteinesulfinic acid |
| mGlu and NMDA agonist | |
| 0217 | D-Glutamic acid |
| Endogenous, non-selective agonist. Less active enantiomer | |
| 0218 | L-Glutamic acid |
| Endogenous, non-selective agonist | |
| 0285 | Ibotenic acid |
| Non-selective mGlu agonist, also NMDA agonist | |
Antagonists |
|
| Cat No | Product Name / Activity |
| 1112 | ACPT-II |
| Competitive mGlu receptor antagonist | |
| 3699 | DL-AP4 Sodium salt |
| Broad spectrum EAA antagonist | |
| 0102 | D-AP4 |
| Broad spectrum EAA antagonist. Less potent enantiomer | |
| 0101 | DL-AP4 |
| Broad spectrum EAA antagonist | |
| 0112 | γDGG |
| Broad spectrum glutamate receptor antagonist | |
| 0223 | Kynurenic acid |
| Broad spectrum EAA antagonist | |
Other |
|
| Cat No | Product Name / Activity |
| 0310 | (RS)-4-Carboxy-3-hydroxyphenylglycine |
| Broad spectrum EAA ligand | |
| 0321 | (RS)-4-Carboxyphenylglycine |
| Broad spectrum EAA ligand | |
| 5785 | MDNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate | |
| 1490 | MNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate | |
Pain Research Product Guide
Our Pain guide highlights over 280 products for Pain research.
Request copyDownload PDFmGlu Receptors Scientific Review
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyDownload PDFEpilepsy Life Science Poster
Written by Alsa Pitkänen and Xavier Ekolle Ndode-Ekane, this poster summarizes current knowledge about how epilepsy develops.
Request copyDownload PDFLearning and Memory Life Science Poster
Written by Clea Warburton and Zafar Bashir
Our Learning and Memory poster gives an overview of the cellular mechanisms underlying recognition memory and its links to long-term depression.
Request copyDownload PDFParkinson's Life Science Poster
Written by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF